Ophthalmics Collaboration and Licensing Deals Collection, 2019-2024: Leading Deals by Value, Most Active Dealmakers, Benchmark Analysis, Financial Terms, and More [Yahoo! Finance]
LowReport
Ophthalmics Collaboration and Licensing Deals Collection, 2019-2024: Leading Deals by Value, Most Active Dealmakers, Benchmark Analysis, Financial Terms, and More [Yahoo! Finance]
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
LowReport
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
LowReport
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $45.00 price target on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $63.00. They now have an "outperform" rating on the stock.
LowReport
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at BMO Capital Markets from $70.00 to $63.00. They now have an "outperform" rating on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $58.00. They now have a "buy" rating on the stock.
LowReport
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $58.00. They now have a "buy" rating on the stock.
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2024 Featuring 843 Market Players - Deals Listed by Company A-Z, Headline Value, Therapeutic Area, and Technology Type [Yahoo! Finance]
LowReport
Co-development Deals in Pharmaceuticals and Biotechnology 2016 to 2024 Featuring 843 Market Players - Deals Listed by Company A-Z, Headline Value, Therapeutic Area, and Technology Type [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: